AUTL

AUTL

USD

Autolus Therapeutics plc American Depositary Share

$2.240-0.130 (-5.485%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigtes Königreich

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$2.370

Hoch

$2.370

Tief

$2.210

Volumen

0.19M

Unternehmensfundamentaldaten

Marktkapitalisierung

596.1M

Branche

Biotechnologie

Land

United Kingdom

Handelsstatistiken

Durchschnittliches Volumen

2.19M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $1.105Aktuell $2.240Hoch $5

Ähnliche Nachrichten

Analyst Upgrades

Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $10 price target.

Mehr anzeigen
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
GlobeNewswire

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent

Mehr anzeigen
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityOpinion follows FDA approval and

Mehr anzeigen
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)